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Abstract: Background: Targeted drugs to the autophagy processes are emerging in clinical trials. The aim of this 
work is to assess the magnitude of autophagic expression in renal angiomyolipoma. Methods: Fourteen cases of re-
nal angiomyolipoma were recruited. Anti-LC3B-II and anti-phospho-S6K were detected by Western blot analysis. For 
immunohistochemical staining, sections were stained with the antibodies LC3B-II and cathepsin-K. LC3B-II was also 
analyzed by immunofluorescence. We have also carried out electron microscopy analysis on tumor cells. Results: 
13 classic and 1 epithelioid renal angiomyolipoma were recruited. The Western-blot LC3B-II analysis shows increas-
ing in protein expression in all cases, however quantitative protein expression ranged from 1 to 15 (mean 5). The 
autophagosome protein LC3B-I also significantly increased in all tumor extraction. The expression of LC3B-II protein 
was confirmed in tumoral samples by immunofluorescence. The lysosomal marker cathepsin-K was observed by 
immunohistochemistry on all tumours. The Western-blot ph-S6K analysis showed significant protein overexpression 
along all cases after evaluation of the quantitative S6K/Ponceaus ratio. In 6/14 (52%) the expression was high, with 
a quantitative increase of ≥3 fold induction in 4 angiomyolipoma compared to normal tissue. At electron microscopy, 
cancer cells evidenced round or oval electron-dense granules associated with membranes and granules with double 
membrane. Conclusion: Both autophagic LC3B-II and ph-S6K molecules are over-represented in both epithelioid 
and classic renal angiomyolipoma and a combined use of inhibitors to the autophagic and mTOR processes may be 
designed in clinical trials, when enrolling patients affected by tumours in tuberous sclerosis or angiomyolipoma at 
risk of bledding. 
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Introduction
Autophagy is a self-digesting mechanism that 
cells adopt following nutrient deprivation or 
stressful stimuli to deliver proteins and organ-
elles to lysosomes, where they are degraded 
and recycled [1, 2]. Autophagy can act also as a 
protective mechanism during a stressful epi-
sode, however, if prolonged, it can lead to cell 
death, named ‘autophagic cell death’ [3, 4]. 
Recent studies have brought to attention the 
possible autophagy role in survival and growth 
of cancer cells [5]. The cellular context may pro-
mote and/or inhibit autophagy in cancer cells. 
Notably, the well known mTOR protein complex 
is an autophagic process inhibitor and it is 
described constitutively active in the tumoral 
model of mTOR activation such as renal angio-
myolipoma [6]. Renal angiomyolipomas occa-
sionally occur sporadically and as part of tuber-
ous sclerosis complex (TSC) and TSC is caused 
by mutations in either TSC1 or TSC2 suppres-
sor genes [7, 8], resulting in increased mamma-
lian target of rapamycin (mTOR) activity. The 
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research on autophagy as a mechanism for 
regulating cell death or survival has acquired 
huge interest in recent years, not only as a cell 
response to starvation but also as a mecha-
nism involved in tumorigenesis, neurodegener-
ation and non-caspase-linked forms of cell 
death [2, 5, 9]. Even more importantly, drug 
inhibitors of the autophagy process have been 
developed and additional trials are under inves-
tigation in patients affected by malignant 
tumors. In the context of the kidney, the clinical 
relevance of using mTOR inhibitors for the treat-
ment of angiomyolipomas is accepted, being 
tumors regressed somewhat during sirolimus 
therapy and some patients with lymphangi-
oleiomyomatosis had improvement in spiromet-
ric measurements and gas trapping that per-
sisted after treatment. Suppression of mTOR 
signaling constitute an ameliorative treatment 
in patients with the tuberous sclerosis complex 
or sporadic lymphangioleiomyomatosis.
Morphologically, autophagic cells show multi-
ple cytoplasmic double-membrane vacuoles, 
called autophagosomes, which fuses with a 
lysosome to be degraded. Elongation of the 
autophagosomal membrane entails conjuga-
tion of MAP1-light chain 3B (LC3B) protein to 
phosphatidylethanolamine [10]. Few reports 
assess both activation of the LC3B and mTOR 
pathway in renal angiomyolipomas, by using dif-
ferent techniques on the same cohort of 
tumors. Assessment of biomarkers on the 
same tumors may promote use of combined 
targeted drugs or alternation of drugs which 
target to different pathways in patients affect-
ed by variants of renal angiomyolipoma.
The aim of this work is to verify the existence 
and magnitude of autophagic mechanisms in 
renal angiomyolipoma, which is one of the can-
cer model representing activation of the mTOR 
pathway in order to understand if administra-
tion of autophagic process inhibitors could 
have a rationale for a medical therapy in this 
lesion.
Materials and methods
Ethics statement
The University and Hospital Trust’s Institutional 
Board approved all research involving human 
participants in accordance with the Helsinki 
Declaration of 1975. Informed consent was 
obtained in writing from living patients or rela-
tives for all tissues used in this study from the 
Transplant Kidney Center (Protocol PRIHTA 
2014-00453).
Tissue samples
We selected from the Department of Diag- 
nostics and Public Health, University and 
Hospital Trust of Verona, a series of renal angio-
myolipomas, diagnosed by uropathologists 
(GM, MB, CG, AE) with morphology and panel of 
antibodies. Each tumor was accompanied by 
an adequate sample from the adjacent renal 
parenchyma, used as control. 
Protein extraction and western blot analyses
After deparaffinization and rehydration of tis-
sue sections, proteins were extracted using 
Qproteome FFPE Tissue Kit (Qiagen). Briefly, 
the area of interest was excised with a needle 
and transferred to a collection tube containing 
100 μl of extraction buffer. 
The sample was vortexed and incubated in 
100°C water bath for 20 minutes and then in 
80°C thermomixer for 2 h with shake at 750 
rpm. 
After heat-treatment, the sample was cooled to 
4°C for 5 minutes and centrifuged (14000 g, 
15 minutes, 4°C). The supernatant was trans-
ferred to a new collection tube and stored at 
-20°C.
Protein quantification was performed by using 
the Bio-Rad protein assay kit according to man-
ufacturer’s instructions. 25 μg of extracted 
lysates was resolved in 10% polyacrylamide 
SDS-PAGE gel in a BioRad Mini Protean tetra 
cell system at 150 V for 1 h.
Electrophoresed proteins were transferred into 
a nitrocellulose membrane at 250 mA for 90 
minutes. The membranes were blocked in TBST 
(100 mM Tris pH 7.5, 0.9% NaCl, 0.1% Tween 
20) plus 5% non-fat dry milk for 1 h at RT with 
constant shaking and probed overnight at 4°C 
with a rabbit polyoclonal anti LC3B (1:1,00) 
(Cell Signaling, Danvers, MA, USA) antibodies, 
rabbit monoclonal anti-phospho S6K (1:1,000) 
(Cell Signaling, Danvers, MA, USA).
They were incubated O.N. at 4°C with the indi-
cated antibodies, washed three times with 
TBST and incubated with the specific second-
ary anti-mouse or anti-rabbit peroxidase-conju-
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gated anti IgG antibody. After three washes 
with TBST, the immunoblots were visualized 
with ECL plus (Amersham/GE HealthcareEurope 
GmgH, Munchen, Germany).
Expression levels of each marker was quanti-
fied with ImageJ densitometric analysis.
Immunofluorescence analyses
Paraffin-embedded tissue block were cut into 
2-3 μm sections and mounted on adhesion 
microscope glass slides. After the sections 
were dewaxed and rehydrated. Antigen retrieval 
was performed in prewarmed citrate buffer (pH 
6 temp 95°C) for 30 minutes. The sections 
were cooled to room temperature and then 
incubated with a protein block serum free solu-
tion for 15 minutes at RT to block non-specific 
binding.
For immunofluorescence staining, sections 
were incubated with primary anti LC3B (1:100) 
(Abgent, San Diego, CA, USA) antibodies, at RT 
for 60 minutes. Slides were then incubated 
with the secondary FITC-conjugated antibody 
(1:100) (Donkey, anti-rabbit Jackson Immuno- 
research) at RT for 30 minutes. Nuclei were 
stained with Prolong Gold antifade reagent with 
DAPI (Invitrogen Molecular Probe). Slides were 
analysed by a Olympus BX61 microscope.
Immunohistochemical analysis
Paraffin-embedded tissue block were cut into 
2-3 μm sections and mounted on adhesion 
microscope glass slides.
For immunohistochemical staining, sections 
were stained in an autostainer Leica Bond 
System with the following antibodies: LC3B 
Polyclonal (1:100) (Abcam, Cambridge, UK), 
Cathepsin K (1:300) (Abcam, Cambridge, UK), 
CD68 (1:50) (Dako, Carpinteria, CA, USA), CD68 
(1:50) (Dako, Carpinteria, CA, USA).
Table 1. Clinico-pathological features of renal angiomyolipomas
Cases Age Sex Localization Synchronous localization Diameter (cm) Type
1 42 M Polar localization no 7.5 AML
Classic
2 42 F Mesorenal region yes 1.4 AML
Classic
3 42 F Mesorenal region yes 4.5 AML
epithelioid
4 60 M Polar localization no 2.5 AML
classic
5 52 F Mesorenal region yes 7 AML
classic
6 61 F Mesorenal region no 6.5 AML
classic
7 66 F Polar localization no 1.4 AML
classic
8 60 F Polar localization no 7 AML
classic
9 49 F Mesorenal region yes 4.2 AML 
classic
10 62 F Polar localization no 1,9 AML 
classic
11 76 F Mesorenal region no 1.3 AML 
classic
12 59 F Mesorenal region no 6 AML
classic
13 69 F Mesorenal region yes 5.8 AML
classic
14 31 F Mesorenal region yes 10 AML
classic
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Appropriate positive controls for each antibody 
were run concurrently and showed adequate 
immunostaining.
Electron microscopy
The tissue was fixed in formalin and then 
washed with phosphate buffer and fixed with 
glutaraldehyde at 2%; subsequently it was 
placed in 1% osmium tetroxide with ferricianide 
potassium for 1 hour. Finally, the tissue was 
dehydrated with alcohol and associated in a 
mixture of Epon and Araldite.
Ultrathin sections were obtained in ultracut 
microtome (Reichert-Jung, Wien, Austria) by 
cutting with diamond, were stained with uranyl 
acetate of lead citrate, and finally valued at 
electron microscope Zeiss EM-l O (Oberkochen, 
Germany).
Results
Clinico-pathological findings
In Table 1 the main clinico-pathological charac-
teristics of 14 (Case no. 1-14) renal angiomyoli-
poma cases have been summarized.
13 classic angiomyolipoma and 1 epithelioid 
variant of renal angiomyolipoma (predominant-
ly epithelioid and muscle differentiation) were 
recruited (Figure 1A, 1B).
The selected patients are ten females and two 
males aged between 31 and 76 years old.
Renal neoplasia had a diameter ranging from 
1.4 cm to 10 cm. Polar localization in Case 1, 4, 
7, 8 and 10 of the lesions were showed in the 
capsular region.
The lesions of case 2, 3, 5, 6, 9, 11, 12, 13 and 
14 were located in the mesorenal region, as 
cortical/capsular localization.
Western blot finale results
The Western blot ph-S6K analysis shows signifi-
cant protein overexpression along all cases 
after evaluation of the quantitative S6K/
Ponceaus ratio.
In 6 out of 14 (42%) we observed high expres-
sion. In cases 1, 2, 4, 14 we have a quantitative 
increase of more than 3 fold induction in angio-
Figure 1. Histology and Immunohistochemical staining of Renal Angiomyolipomas: Hematoxylin and eosin stains 
showing a classic angiomyolipoma (A) a case with predominant epithelioid and muscle differentiation (epithelioid 
angiomyolipoma) (B). Lysosomal markers expression in renal angiomyolipoma samples. A section with expression 
of LC3B (C) and a case showing strong positivity for Cathepsin K (D).
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myolipoma tissue compared to normal tissue, 
used as control. In case 13 a quantitative 
increase of more than 2 fold induction and a 
slight quantitative increase of fold induction in 
case 11 (Figure 3).
The Western blot LC3B-II (using anti LC3 pro-
tein antibody) analysis shows increasing in pro-
tein expression in all cases. Quantitative pro-
tein expression ranged from 1 to 15 (mean 5) 
(Figure 2).
The phosphoethanolaminated active form of 
the autophagosome protein LC3B-I, significant-
ly increased in tumor tissues extraction (Figure 
2).
Immunofluorescence finale results
The expression of LC3B-II protein was con-
firmed in tumoral samples with immunofluores-
cence analysis (Figure 4).
Immunohistochemical finale results
Lysosomal marker expression Cathepsin K 
were observed, by immunohistochemical analy-
sis, in all cases in a form of strong expression 
(Figure 1D). Normal renal tissues were nega-
tive for any lysosomal markers.
Electron microscopy findings
Cancer cells were elongated, polygonal or 
rounded, with few intracytoplasmic material. In 
the cytoplasm it was observed glycogen, mito-
chondria, round or oval and electron-dense 
granules, associated with membranes. We also 
noted a number of granules with double 
membrane.
Discussion
We report that: 1) renal angiomyolipoma nota-
bly evidence an high expression of LC3B and 
Figure 2. LC3B western blot in renal angyomiolipoma: A. Normal and renal angiomyolipoma protein extraction ana-
lyzed with western blot. The membranes were incubated with anti-LC3B antibody. Protein levels were normalized 
with Ponceau S staining. B. Quantitative evaluation on LC3B expression levels. The bands were scanned as digital 
peaks and the areas of the peaks were calculated in arbitrary units. The value of Ponceau S was used as a nor-
malizing factor. Values are the means of three independent experiments (± SD). Statistical analysis: P<0.05 LC3B 
versus CTRL.
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ph-S6K; 2) both autophagic and mTOR path-
ways are over-represented in both classic and 
epithelioid variant; 3) a combined use of mTOR 
and autophagic inhibitors may be designed in 
clinical trials for the enhancement of medical 
therapy when enrolling patients affected by 
tumors in tuberous sclerosis or angiomyolipo-
ma at risk of bleeding.
We selected from our institute archives, 14 re- 
nal angiomyolipoma cases on which we ma- 
de immunohistochemical, immunofluorescen- 
ce and western blot studies to search protein 
involved in autophagy mechanisms (like LC3B-
II) and factors able to adjust mTOR functional 
expression (like ph-S6K).
Angiomyolipoma, although is a benign tumor, 
can present risks. In fact, tumor size greater 
than 4 cm is associated with an increased 
bleeding risk, that can lead to retroperitoneal 
bleeding. Moreover, the presence of multiple 
lesions, characteristic event of the form associ-
ated with the tuberous sclerosis syndrome, 
may lead to progressive renal failure. There are, 
in the renal angiomyolipoma tumor group, rare 
forms with high malignant potential, such 
as the aggressive form of the epithelioid 
angiomyolipoma.
oid and classic variants. The induction of 
autophagy was further documented using anti 
LC3-II protein antibody (Figure 2). The expres-
sion of LC3B-II protein, the phosphoethanol-
aminated active form of the autophagosome 
protein LC3B-I, significantly increased in tumor 
tissues extraction and showed differences 
among the quantitative analysis (Figure 2). In 6 
our of 14 (52%) we observed high expression: 
we observed a quantitative increase of more 
than 3 fold induction in 4 angiomyolipoma tis-
sues compared to normal tissue, used as con-
trol and in one case a quantitative increase of 
more than 2 fold induction and a slight quanti-
tative increase of fold induction in an additional 
case.
Again, the expression of LC3B-II protein was 
confirmed in all tumoral samples with immuno-
fluorescence and immunohistochemical analy-
sis (Figures 1C, 4). 
There are several molecules that can inhibit at 
various levels autophagy, including chloro-
quine, an antimalarial drug [12, 13]. It blocks 
the fusion between autophagosome and lyso-
some and shows significantly reducing tumor 
growth in mice models [14]. mTOR inhibitors 
drugs are known as antitumoral in renal angio-
Figure 3. Phospho S6K western blot in renal angiomyolipoma: A. The nor-
mal and renal angiomyolipoma protein extraction analyzed with western 
blot. The membranes were  incubated with anti-phospho S6K antibody. 
Protein levels were normalized with Ponceau S staining. B. Quantitative 
evaluation on Phospho S6K expression levels. The bands were scanned 
as digital peaks and the areas of the peaks were calculated in arbitrary 
units. The value of Ponceau S was used as a normalizing factor. Values are 
the means of three independent experiments (± SD). Statistical analysis: 
P<0.05 Phospho S6K versus CTRL.
The ribosomal protein S6K (S6 
kinase) represents an exten-
sively studied effector of the 
TORC1 complex; therefore the 
presence of the phosphorylat-
ed form is used in order to veri-
fy the activation of mTOR, who- 
se directed antibody is often 
not practical [11]. Moreover, 
western blot analyses showed 
increase levels of ph-S6K along 
all samples (Figure 3), thus 
mTOR pathway is activated in 
renal angiomyolipoma.
Notably, the mTOR protein com-
plex is an autophagic process 
inhibitor and it has been report-
ed constitutively active in renal 
angiomyolipoma tumor cells 
[12]. The autophagic process 
encounters different molecules 
along the pathway. In our study 
we shed light to a robust mark-
er of autophagy such as the 
LC3B biomarker in renal angio-
myolipoma and evidenced the 
activation in both the epitheli-
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myolipoma, such as rapamycin (Sirolimus); in 
the discontinuation drugs use is observed, 
however, a progression of the tumor [15].
Chloroquine and mTOR inhibitors drug combi-
nation, on experimental models, proved more 
effective than the single molecule use, this 
demonstrates a synergistic effect.
Microtubule-associated protein light chain 3B 
(LC3B) is a soluble protein with a molecular 
mass of ~17  kDa that is spread ubiquitously in 
mammalian tissues and cultured cells.
During autophagy, a cytosolic form of LC3B 
(LC3B-I) is conjugated to phosphatidylethanol-
amine to form LC3-phosphatidylethanolamine 
conjugate (LC3B-II), which is included in auto- 
phagosomal membranes. Autophagosomes fu- 
se with lysosomes to form autolysosomes, and 
intra-autophagosomal components are degrad-
ed by lysosomal hydrolases.
At the same time, LC3B-II in autolysosomal 
lumen is degraded. Thus, lysosomal turnover of 
the autophagosomal marker LC3B-II reflects 
starvation-induced autophagic activity, and de- 
tecting LC3B by immunohistochemistry, immu-
nofluorescence has become a reliable method 
for monitoring autophagy.
We have also verified the lysosomal markers 
presence in tumor cells by using cathepsin-k 
and CD68 [16]. Finally, we carried out a study 
by electron microscopy to verify double mem-
brane organelles presence into the neoplastic 
cells cytoplasm [17-21]. At electron microscopy, 
cancer cells were elongated, polygonal or 
rounded, with few intracytoplasmic material. In 
the cytoplasm it was observed glycogen, mito-
chondria, round or oval and interestingly elec-
tron-dense granules, associated with mem-
branes. We also noted a number of granules 
with double membrane. In 1991 was de- 
scribed the constant expression of a melano-
genesis marker in renal angyomiolipoma 
(HMB45-gplOO) and particularly in the epitheli-
oid form of angiomyolipoma [17]. These intracy-
toplasmatic granules previously observed in 
angiomyolipoma, also observed in our study, 
were described by Yu et al. [22] as possible 
renin granules, and considered forms of preme-
lanosomes. These granules were shown also 
present in clear cell sugar tumor of the pancre-
as [23] and in lymphangioleiomyomatosis [24]. 
Following this clarification, the CD68 lysosomal 
marker, in the classical form and in the epithe-
lioid angiomyolipoma [25, 26] was initially re-
considered to be due to the presence of pre-
melanosomes. Recently, the cathepsin K find-
ings, a lysosomal protein, in angiomyolipoma 
cells tumor [27], again observed also in the 
actual study, suggested the relationship 
between granules to forms of lysosomes.
The assessment of the LC3B-II form or the rela-
tionship between LC3B-II and LC3B-I content is 
currently considered as a simple, quick proce-
dure to verify the presence of cell autophagy 
[28] and its use is advised in recently published 
guidelines for the interpretation of assays mon-
itoring autophagy [2].
Figure 4. LC3B immunofluorescence in renal angiomyolipoma: Anti-human LC3B positive expression in normal and 
renal angiomyolipoma (immunofluorescence green).
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In conclusion, in the actual study, we observed 
LC3B presence by immunofluorescence and 
western blot analysis. We verified the constant 
presence of LC3B-II in renal angiomyolipoma 
tumor cells. The increase of LC3B in this case 
may be explained by the activation of mTOR 
pathway and autophagy is not mutually exclu-
sive. Both pathways may be at least in part acti-
vated in the tumor processes. Therefore, the 
autophagy process in renal angiomyolipoma 
constitutes a tissue-based rationale for using 
combination or alternative sequential use of 
autophagy inhibitors (such as cloroquine), and 
mTOR inhibitors in patients affected by pure 
epithelioid angiomyolipoma [29], lymphangi-
oleiomyomatosis or patients affected by multi-
ple angiomyolipomas in tuberous sclerosis syn-
drome or in angiomyolipoma (>4 cm) at risk of 
bleeding [26, 29].
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